FDA approves LLY’s Trulicity (dulaglutide), a weekly GLP-1 for T2D: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm Trulicity will compete against NVO’s Victoza and AZN’s Bydureon and Byetta (among other agents).